Education
About Us
Working with TipRanks
Follow Us
LivaNova PLC (LIVN)
:LIVN
LIVN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$36.85 - $64.48
Previous CloseN/A
Volume66.13K
Average Volume (3M)829.36K
Market Cap
$2.13B
Enterprise Value$2.88B
Total Cash (Recent Filing)$67.91M
Total Debt (Recent Filing)$7.05M
Price to Earnings (P/E)34.2
Beta1.10
Next Earnings
May 07, 2025EPS Estimate
0.76Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.15
Shares Outstanding54,351,765
10 Day Avg. Volume657,150
30 Day Avg. Volume829,361
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)N/A
Price to Sales (P/S)1.71
Price to Cash Flow (P/CF)6.80
P/FCF Ratio7.90
Enterprise Value/Market Cap1.35
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit3.31
Enterprise Value/Ebitda14.23
Forecast
1Y Price Target
$61.29Price Target Upside56.03% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
---
LivaNova News
PremiumCompany Announcements
LivaNova Faces €333 Million Liability Ruling
PremiumCompany Announcements
LivaNova PLC Reports Strong Growth Amid Challenges
---
Bulls Say, Bears Say
Bulls Say
Core Business GrowthMultiple drivers in the core business support durable 6-7% organic growth.
Liability ManagementLIVN expects to record a liability of ~$363M, which is lower than the ~$493M initially disclosed, improving its financial position.
Market Share And CompetitionGetinge's decision to divest its surgical perfusion business could be a modest positive for LIVN, which already has a significant market share in this area.
Bears Say
Competition RiskPotential competition risk is anticipated from NeuroPace's responsive neurostimulation technology, which could impact a significant portion of the company's volume.
Epilepsy Segment PerformanceThere are execution issues affecting the global epilepsy market, with significant personnel changes and a decline in performance.
Litigation OverhangThe company continues to face the overhang of outstanding litigation (SNIA).
---
Ownership Overview
0.27% Insiders
29.47% Mutual Funds
30.60% Other Institutional Investors
20.33% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
LIVN FAQ
What was LivaNova PLC’s price range in the past 12 months?
LivaNova PLC lowest stock price was $36.85 and its highest was $64.47 in the past 12 months.
What is LivaNova PLC’s market cap?
LivaNova PLC’s market cap is $2.13B.
When is LivaNova PLC’s upcoming earnings report date?
LivaNova PLC’s upcoming earnings report date is May 07, 2025 which is in 35 days.
How were LivaNova PLC’s earnings last quarter?
LivaNova PLC released its earnings results on Feb 25, 2025. The company reported $0.81 earnings per share for the quarter, beating the consensus estimate of $0.801 by $0.009.
Is LivaNova PLC overvalued?
According to Wall Street analysts LivaNova PLC’s price is currently Undervalued.
Does LivaNova PLC pay dividends?
LivaNova PLC does not currently pay dividends.
What is LivaNova PLC’s EPS estimate?
LivaNova PLC’s EPS estimate is 0.76.
How many shares outstanding does LivaNova PLC have?
LivaNova PLC has 54,351,765 shares outstanding.
What happened to LivaNova PLC’s price movement after its last earnings report?
LivaNova PLC reported an EPS of $0.81 in its last earnings report, beating expectations of $0.801. Following the earnings report the stock price went down -15.758%.
Which hedge fund is a major shareholder of LivaNova PLC?
Currently, no hedge funds are holding shares in LIVN
---
LivaNova Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$61.29 (56.03% Upside)
$61.29 (56.03% Upside)
Blogger Sentiment
Bullish
LIVN Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 1.2M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $63.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 1.2%
Last 30 Days ▲ 2.7%
Last 30 Days ▲ 2.7%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-29.78%
12-Months-Change
Fundamentals
Return on Equity
4.87%
Trailing 12-Months
Asset Growth
3.16%
Trailing 12-Months
Company Description
LivaNova PLC
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates through three segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. The Neuromodulation segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. It is also involved in the development and clinical testing of the VITARIA System for treating heart failure through VNS. The Advanced Circulatory Support segment develops, produces, and sells temporary life support products, such as cardiopulmonary and respiratory support solutions. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. It sells its products through direct sales representatives and independent distributors. The company has a research collaboration with Verily to capture clinical biomarkers of depression. LivaNova PLC was founded in 1987 and is headquartered in London, the United Kingdom.
---
LIVN Company Deck
---
LIVN Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected strong financial performance with significant growth in key segments and positive clinical milestones. However, challenges in the epilepsy segment and uncertainties regarding SNIA litigation and tax rate increases were noted.Read More>---
LIVN Stock 12 Month Forecast
Average Price Target
$61.29
▲(56.03% Upside)
Technical Analysis
Boston Scientific
―
Edwards Lifesciences
―
Medtronic
―
Stryker
―
Zimmer Biomet Holdings
―
Best Analysts Covering LIVN
1 Year
1 Year Success Rate
7/20 ratings generated profit
1 Year Average Return
-11.84%
assigned a buy rating 5 months ago
Copying Adam Maeder's trades and holding each position for 1 Year would result in 35.00% of your transactions generating a profit, with an average return of -11.84% per trade.
---